Form 4: Pacira BioSciences SVP Lauren Riker Sells Shares

Senior Vice President of Finance Lauren Riker sold 6,115 shares of Pacira BioSciences common stock via a 10b5-1 plan.

Summary

• Lauren Riker, Senior Vice President of Finance at Pacira BioSciences, sold 6,115 shares of common stock.
• The transaction occurred on June 11, 2026, at a price of $23.50 per share.
• Following the sale, the reporting person retains beneficial ownership of 62,284.242 shares.
• The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on March 12, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a standard executive financial management activity.

Positives

• The transaction was conducted under a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market, potentially signaling that management believes the stock price is fully valued.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine corporate governance events and generally do not reflect a change in the company's fundamental business outlook or strategic direction.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is the industry standard for corporate executives to manage personal liquidity while maintaining compliance with SEC regulations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was executed via a pre-arranged plan.

Key Dates

Keywords

Pacira BioSciences, PCRX, Insider Trading, Form 4, Stock Sale, Executive Compensation